Inogen (INGN) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Aug, 2026Executive summary
Q2 2026 revenue reached $95.1 million, up 3% year-over-year, driven by strong international growth and new product launches, while U.S. rentals declined and B2B sales offset DTC channel pressure.
International revenue grew 14.8% to $41.3 million, marking sustained double-digit growth and contributing 43.4% of total revenue.
Adjusted EBITDA improved 15% year-over-year to $2.4 million, reflecting operational efficiency gains.
GAAP net loss narrowed to $3.9 million from $4.2 million in Q2 2025; adjusted net loss improved to less than $0.1 million.
Continued investment in product innovation, commercial leadership, and international expansion, with a focus on profitability and operational discipline.
Financial highlights
Total revenue: $95.1 million (+3% year-over-year); U.S. sales: $42.3 million (-2.3% year-over-year); International sales: $41.3 million (+14.8% year-over-year); U.S. rentals: $11.6 million (-11.8%).
Adjusted EBITDA: $2.4 million (Q2 2026) vs. $2.1 million (Q2 2025); Adjusted net loss: <$0.1 million (improved from $0.7 million loss).
Gross margin: 45.5% (up from 44.8%); adjusted gross margin: 45.6%; gross margin on rental revenue declined to 40.6%.
Operating cash flow: $2.9 million; Free cash flow: $1.0 million (up from $0.5 million in Q2 2025); Cash, equivalents, and marketable securities: $106.8 million; No debt.
Repurchased 1,145,150 shares for $7.5 million in H1 2026.
Outlook and guidance
Full-year 2026 revenue guidance lowered to $355–$361 million (approx. 3% growth at midpoint), down from prior $366–$373 million.
Full-year adjusted EBITDA guidance raised to approximately $4.0 million, a 48% increase from 2025.
Q3 2026 revenue expected to be in line with Q3 2025 ($92.4 million), reflecting U.S. channel mix and international distributor inventory timing.
Management expects existing capital resources and cash from operations to be sufficient for at least the next 12 months.
Latest events from Inogen
- Achieved a financial turnaround and expanded into new respiratory care markets with innovative products.INGN
Corporate presentation6 Aug 2026 - Diversified platform, new products, and financial turnaround position for sustained growth.INGN
Corporate presentation11 Jun 2026 - Directors, auditors, and compensation approved; board declassification amendment failed.INGN
AGM 20265 Jun 2026 - Revenue up 3.4% to $85.1M, driven by international growth despite higher net loss.INGN
Q1 202611 May 2026 - Proxy details director elections, governance reforms, and expanded equity incentives for 2026.INGN
Proxy filing28 Apr 2026 - Shareholders will vote on board declassification, equity plan expansion, and key governance changes.INGN
Proxy filing17 Apr 2026 - New products and leadership drive growth, margin expansion, and strategic transformation.INGN
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Diversifying into respiratory care, achieving financial turnaround, and launching innovative products.INGN
Company presentation20 Mar 2026 - Diversified portfolio and innovation pipeline set to drive growth and profitability.INGN
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026